CTSC shows Stenoparib to be effective in blocking replication of SARS-CoV-2


  • The COVID-19 Testing Service Center (CTSC) was establish to perform in vitro testing of Coronavirus.

  • Test results show that Stenoparib, an ovarian cancer drug already approved by the FDA, is effective in combating coronavirus.

  • When used in combination with Remdesivir, the drugs work in tandem to successfully inhibit viral multiplication.

  • The results are published in mBio Journal: Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro



Established at the onset of the pandemic, the COVID-19 Testing Service Center (CTSC) started testing devices and potential treatments against Coronavirus. After much success with Stenoparib, an ovarian cancer drug, the findings are published in mBio Journal.


What does this mean for potential treatments? The drug may progress to clinical trials soon. The publication documents the potential of combination drug therapy when used with Remdesivir, each hitting different mechanisms that inhibit the virus, making the use of both very effective at eliminating the infection.


The CTSC continues to test the drug on the new variants, including the U.K., South African and Brazilian variants. There is no reason that Stenoparib won’t be equally effective. Hopefully, the continued testing will prove the hypothesis, arming the medical community with new options against this deadly pandemic.



Read Original Article at 12news.com


You may also like

Leave a comment